APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Agents

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroprotective Agents Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchNeuroprotective Agents Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Agents Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Neuroprotective Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Agents Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Agents Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Neuroprotective Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroprotective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroprotective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroprotective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroprotective Agents market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroprotective Agents market include Allon Therapeutics, Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and NeuroVive Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroprotective Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroprotective Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroprotective Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroprotective Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroprotective Agents Segment by Company

Allon Therapeutics

Ceregene

Genervon Biopharmaceuticals

Neuren Pharmaceuticals

NeuroVive Pharmaceutical

Neuroprotective Agents Segment by Type

Ophthalmic Diseases

Neurodegenerative Disorders

Cerebrovascular Diseases

Traumatic CNS Injuries

Neuroprotective Agents Segment by Application

Hospitals

Clinics

Others

Neuroprotective Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroprotective Agents status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroprotective Agents market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroprotective Agents significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroprotective Agents competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroprotective Agents market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroprotective Agents industry.

Chapter 3: Detailed analysis of Neuroprotective Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroprotective Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroprotective Agents in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroprotective Agents Industry Trends Table 2. Neuroprotective Agents Industry Drivers Table 3. Neuroprotective Agents Industry Opportunities and Challenges Table 4. Neuroprotective Agents Industry Restraints Table 5. Global Neuroprotective Agents Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroprotective Agents Revenue Share by Company (2021-2026) Table 7. Global Neuroprotective Agents Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Neuroprotective Agents Sales Volume Share by Company (2021-2026) Table 9. Global Neuroprotective Agents Average Price (US$/ton) of Company (2021-2026) Table 10. Global Neuroprotective Agents Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroprotective Agents Key Company Manufacturing Base & Headquarters Table 12. Global Neuroprotective Agents Company, Product Type & Application Table 13. Global Neuroprotective Agents Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroprotective Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ophthalmic Diseases Table 18. Significant Companies of Neurodegenerative Disorders Table 19. Significant Companies of Cerebrovascular Diseases Table 20. Significant Companies of Traumatic CNS Injuries Table 21. Global Neuroprotective Agents Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 22. Global Neuroprotective Agents Sales Volume by Type (2021-2026) & (k tons) Table 23. Global Neuroprotective Agents Sales Volume by Type (2027-2032) & (k tons) Table 24. Global Neuroprotective Agents Sales Volume Share by Type (2021-2026) Table 25. Global Neuroprotective Agents Sales Volume Share by Type (2027-2032) Table 26. Global Neuroprotective Agents Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neuroprotective Agents Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Neuroprotective Agents Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Neuroprotective Agents Sales Value Share by Type (2021-2026) Table 30. Global Neuroprotective Agents Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Clinics Table 33. Significant Companies of Others Table 34. Global Neuroprotective Agents Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 35. Global Neuroprotective Agents Sales Volume by Application (2021-2026) & (k tons) Table 36. Global Neuroprotective Agents Sales Volume by Application (2027-2032) & (k tons) Table 37. Global Neuroprotective Agents Sales Volume Share by Application (2021-2026) Table 38. Global Neuroprotective Agents Sales Volume Share by Application (2027-2032) Table 39. Global Neuroprotective Agents Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Neuroprotective Agents Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Neuroprotective Agents Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Neuroprotective Agents Sales Value Share by Application (2021-2026) Table 43. Global Neuroprotective Agents Sales Value Share by Application (2027-2032) Table 44. Global Neuroprotective Agents Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 45. Global Neuroprotective Agents Sales by Region (2021-2026) & (k tons) Table 46. Global Neuroprotective Agents Sales Market Share by Region (2021-2026) Table 47. Global Neuroprotective Agents Sales by Region (2027-2032) & (k tons) Table 48. Global Neuroprotective Agents Sales Market Share by Region (2027-2032) Table 49. Global Neuroprotective Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Neuroprotective Agents Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Neuroprotective Agents Sales Value Share by Region (2021-2026) Table 52. Global Neuroprotective Agents Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Neuroprotective Agents Sales Value Share by Region (2027-2032) Table 54. Global Neuroprotective Agents Market Average Price (US$/ton) by Region (2021-2026) Table 55. Global Neuroprotective Agents Market Average Price (US$/ton) by Region (2027-2032) Table 56. Global Neuroprotective Agents Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 57. Global Neuroprotective Agents Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Neuroprotective Agents Sales by Country (2021-2026) & (k tons) Table 59. Global Neuroprotective Agents Sales Market Share by Country (2021-2026) Table 60. Global Neuroprotective Agents Sales by Country (2027-2032) & (k tons) Table 61. Global Neuroprotective Agents Sales Market Share by Country (2027-2032) Table 62. Global Neuroprotective Agents Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Neuroprotective Agents Sales Value Market Share by Country (2021-2026) Table 64. Global Neuroprotective Agents Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Neuroprotective Agents Sales Value Market Share by Country (2027-2032) Table 66. Allon Therapeutics Company Information Table 67. Allon Therapeutics Business Overview Table 68. Allon Therapeutics Neuroprotective Agents Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 69. Allon Therapeutics Neuroprotective Agents Product Portfolio Table 70. Allon Therapeutics Recent Development Table 71. Ceregene Company Information Table 72. Ceregene Business Overview Table 73. Ceregene Neuroprotective Agents Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 74. Ceregene Neuroprotective Agents Product Portfolio Table 75. Ceregene Recent Development Table 76. Genervon Biopharmaceuticals Company Information Table 77. Genervon Biopharmaceuticals Business Overview Table 78. Genervon Biopharmaceuticals Neuroprotective Agents Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 79. Genervon Biopharmaceuticals Neuroprotective Agents Product Portfolio Table 80. Genervon Biopharmaceuticals Recent Development Table 81. Neuren Pharmaceuticals Company Information Table 82. Neuren Pharmaceuticals Business Overview Table 83. Neuren Pharmaceuticals Neuroprotective Agents Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 84. Neuren Pharmaceuticals Neuroprotective Agents Product Portfolio Table 85. Neuren Pharmaceuticals Recent Development Table 86. NeuroVive Pharmaceutical Company Information Table 87. NeuroVive Pharmaceutical Business Overview Table 88. NeuroVive Pharmaceutical Neuroprotective Agents Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 89. NeuroVive Pharmaceutical Neuroprotective Agents Product Portfolio Table 90. NeuroVive Pharmaceutical Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Neuroprotective Agents Distributors List Table 94. Neuroprotective Agents Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Neuroprotective Agents Product Image Figure 2. Global Neuroprotective Agents Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Agents Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroprotective Agents Sales (2021-2032) & (k tons) Figure 5. Global Neuroprotective Agents Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Neuroprotective Agents Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ophthalmic Diseases Image Figure 10. Neurodegenerative Disorders Image Figure 11. Cerebrovascular Diseases Image Figure 12. Traumatic CNS Injuries Image Figure 13. Global Neuroprotective Agents Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 14. Global Neuroprotective Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Neuroprotective Agents Sales Volume Share by Type (2021-2032) Figure 16. Global Neuroprotective Agents Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neuroprotective Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neuroprotective Agents Sales Value Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Others Image Figure 22. Global Neuroprotective Agents Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 23. Global Neuroprotective Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Neuroprotective Agents Sales Volume Share by Application (2021-2032) Figure 25. Global Neuroprotective Agents Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Neuroprotective Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Neuroprotective Agents Sales Value Share by Application (2021-2032) Figure 28. Global Neuroprotective Agents Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 29. Global Neuroprotective Agents Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Neuroprotective Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Neuroprotective Agents Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Neuroprotective Agents Sales Value (2021-2032) & (US$ Million) Figure 33. North America Neuroprotective Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Neuroprotective Agents Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Neuroprotective Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Neuroprotective Agents Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Neuroprotective Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Neuroprotective Agents Sales Value (2021-2032) & (US$ Million) Figure 39. South America Neuroprotective Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Neuroprotective Agents Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Neuroprotective Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Neuroprotective Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Neuroprotective Agents Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Neuroprotective Agents Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Ophthalmic Diseases
  • Neurodegenerative Disorders
  • Cerebrovascular Diseases
  • Traumatic CNS Injuries
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Allon Therapeutics
  • Ceregene
  • Genervon Biopharmaceuticals
  • Neuren Pharmaceuticals
  • NeuroVive Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroprotective Agents Sales Value (2021-2032)
  4. 1.2.2 Global Neuroprotective Agents Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroprotective Agents Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroprotective Agents Market Dynamics
  1. 2.1 Neuroprotective Agents Industry Trends
  2. 2.2 Neuroprotective Agents Industry Drivers
  3. 2.3 Neuroprotective Agents Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Agents Industry Restraints
3 Neuroprotective Agents Market by Company
  1. 3.1 Global Neuroprotective Agents Company Revenue Ranking in 2025
  2. 3.2 Global Neuroprotective Agents Revenue by Company (2021-2026)
  3. 3.3 Global Neuroprotective Agents Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroprotective Agents Average Price by Company (2021-2026)
  5. 3.5 Global Neuroprotective Agents Company Ranking (2024-2026)
  6. 3.6 Global Neuroprotective Agents Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroprotective Agents Company Product Type and Application
  8. 3.8 Global Neuroprotective Agents Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroprotective Agents Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroprotective Agents Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroprotective Agents Market by Type
  1. 4.1 Neuroprotective Agents Type Introduction
  2. 4.1.1 Ophthalmic Diseases
  3. 4.1.2 Neurodegenerative Disorders
  4. 4.1.3 Cerebrovascular Diseases
  5. 4.1.4 Traumatic CNS Injuries
  6. 4.2 Global Neuroprotective Agents Sales Volume by Type
  7. 4.2.1 Global Neuroprotective Agents Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Neuroprotective Agents Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Neuroprotective Agents Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Neuroprotective Agents Sales Value by Type
  11. 4.3.1 Global Neuroprotective Agents Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Neuroprotective Agents Sales Value by Type (2021-2032)
  13. 4.3.3 Global Neuroprotective Agents Sales Value Share by Type (2021-2032)
5 Neuroprotective Agents Market by Application
  1. 5.1 Neuroprotective Agents Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Neuroprotective Agents Sales Volume by Application
  6. 5.2.1 Global Neuroprotective Agents Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroprotective Agents Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neuroprotective Agents Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neuroprotective Agents Sales Value by Application
  10. 5.3.1 Global Neuroprotective Agents Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroprotective Agents Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neuroprotective Agents Sales Value Share by Application (2021-2032)
6 Neuroprotective Agents Regional Sales and Value Analysis
  1. 6.1 Global Neuroprotective Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroprotective Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroprotective Agents Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroprotective Agents Sales by Region (2027-2032)
  5. 6.3 Global Neuroprotective Agents Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroprotective Agents Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroprotective Agents Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroprotective Agents Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroprotective Agents Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroprotective Agents Sales Value (2021-2032)
  12. 6.6.2 North America Neuroprotective Agents Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroprotective Agents Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroprotective Agents Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroprotective Agents Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroprotective Agents Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroprotective Agents Sales Value (2021-2032)
  21. 6.9.2 South America Neuroprotective Agents Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroprotective Agents Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroprotective Agents Sales Value Share by Country, 2025 VS 2032
7 Neuroprotective Agents Country-level Sales and Value Analysis
  1. 7.1 Global Neuroprotective Agents Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroprotective Agents Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroprotective Agents Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroprotective Agents Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroprotective Agents Sales by Country (2027-2032)
  6. 7.4 Global Neuroprotective Agents Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroprotective Agents Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroprotective Agents Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroprotective Agents Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroprotective Agents Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroprotective Agents Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allon Therapeutics
  2. 8.1.1 Allon Therapeutics Company Information
  3. 8.1.2 Allon Therapeutics Business Overview
  4. 8.1.3 Allon Therapeutics Neuroprotective Agents Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allon Therapeutics Neuroprotective Agents Product Portfolio
  6. 8.1.5 Allon Therapeutics Recent Developments
  7. 8.2 Ceregene
  8. 8.2.1 Ceregene Company Information
  9. 8.2.2 Ceregene Business Overview
  10. 8.2.3 Ceregene Neuroprotective Agents Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ceregene Neuroprotective Agents Product Portfolio
  12. 8.2.5 Ceregene Recent Developments
  13. 8.3 Genervon Biopharmaceuticals
  14. 8.3.1 Genervon Biopharmaceuticals Company Information
  15. 8.3.2 Genervon Biopharmaceuticals Business Overview
  16. 8.3.3 Genervon Biopharmaceuticals Neuroprotective Agents Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Genervon Biopharmaceuticals Neuroprotective Agents Product Portfolio
  18. 8.3.5 Genervon Biopharmaceuticals Recent Developments
  19. 8.4 Neuren Pharmaceuticals
  20. 8.4.1 Neuren Pharmaceuticals Company Information
  21. 8.4.2 Neuren Pharmaceuticals Business Overview
  22. 8.4.3 Neuren Pharmaceuticals Neuroprotective Agents Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Neuren Pharmaceuticals Neuroprotective Agents Product Portfolio
  24. 8.4.5 Neuren Pharmaceuticals Recent Developments
  25. 8.5 NeuroVive Pharmaceutical
  26. 8.5.1 NeuroVive Pharmaceutical Company Information
  27. 8.5.2 NeuroVive Pharmaceutical Business Overview
  28. 8.5.3 NeuroVive Pharmaceutical Neuroprotective Agents Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 NeuroVive Pharmaceutical Neuroprotective Agents Product Portfolio
  30. 8.5.5 NeuroVive Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroprotective Agents Value Chain Analysis
  2. 9.1.1 Neuroprotective Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroprotective Agents Sales Mode & Process
  6. 9.2 Neuroprotective Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroprotective Agents Distributors
  9. 9.2.3 Neuroprotective Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst